Patient-tailored design for selective co-inhibition of leukemic cell subpopulations-Reference-Cited by-同舟云学术

Patient-tailored design for selective co-inhibition of leukemic cell subpopulations

Published:2021-02-19 Issue:8 Volume:7 Page:
ISSN:2375-2548
Container-title:Science Advances
language:en
Short-container-title:Sci. Adv.

Author:

Ianevski Aleksandr¹²^ORCID,Lahtela Jenni¹^ORCID,Javarappa Komal K.¹,Sergeev Philipp¹^ORCID,Ghimire Bishwa R.¹^ORCID,Gautam Prson¹^ORCID,Vähä-Koskela Markus¹^ORCID,Turunen Laura¹^ORCID,Linnavirta Nora¹^ORCID,Kuusanmäki Heikki¹³⁴,Kontro Mika⁴^ORCID,Porkka Kimmo⁵^ORCID,Heckman Caroline A.¹,Mattila Pirkko¹^ORCID,Wennerberg Krister¹³^ORCID,Giri Anil K.¹^ORCID,Aittokallio Tero¹²⁶⁷^ORCID

Affiliation:

1. Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.

2. Helsinki Institute for Information Technology (HIIT), Department of Computer Science, Aalto University, Espoo, Finland.

3. Biotech Research and Innovation Centre (BRIC) and Novo Nordisk Foundation Center for Stem Cell Biology (DanStem), University of Copenhagen, Copenhagen, Denmark.

4. Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.

5. Helsinki University Hospital Comprehensive Cancer Center, Hematology Research Unit Helsinki, iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland.

6. Institute for Cancer Research, Department of Cancer Genetics, Oslo University Hospital, Oslo, Norway.

7. Centre for Biostatistics and Epidemiology (OCBE), Faculty of Medicine, University of Oslo, Oslo, Norway.

Abstract

Machine learning and single-cell data inform personalized drug combinations that selectively co-inhibit cancer cell populations.

Funder

Helse Sør-Øst RHF

Novo Nordisk Foundation Center for Basic Metabolic Research

Business Finland

Academy of Finland

Finnish Medical Foundation

Sigrid Jusélius Foundation

Cancer Society of Finland